Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein

Open source

DOI
10.1177/17562848211005708
Published
2021-01
Container
Therapeutic Advances in Gastroenterology
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/17562848211005708,
  title = {Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis},
  author = {David T. Rubin and Walter Reinisch and Thomas Greuter and Paulo G. Kotze and Marcia Pinheiro and Rajiv Mundayat and Eric Maller and Marc Fellmann and Nervin Lawendy and Irene Modesto and Stephan R. Vavricka and Gary R. Lichtenstein},
  year = {2021},
  journal = {Therapeutic Advances in Gastroenterology},
  doi = {10.1177/17562848211005708},
  url = {https://doi.org/10.1177/17562848211005708}
}

RIS

TY  - JOUR
TI  - Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
AU  - David T. Rubin
AU  - Walter Reinisch
AU  - Thomas Greuter
AU  - Paulo G. Kotze
AU  - Marcia Pinheiro
AU  - Rajiv Mundayat
AU  - Eric Maller
AU  - Marc Fellmann
AU  - Nervin Lawendy
AU  - Irene Modesto
AU  - Stephan R. Vavricka
AU  - Gary R. Lichtenstein
PY  - 2021
JO  - Therapeutic Advances in Gastroenterology
DO  - 10.1177/17562848211005708
UR  - https://doi.org/10.1177/17562848211005708
ER  - 

APA

Rubin, D. T., Reinisch, W., Greuter, T., Kotze, P. G., Pinheiro, M., Mundayat, R., Maller, E., Fellmann, M., Lawendy, N., Modesto, I., Vavricka, S. R., & Lichtenstein, G. R. (2021). Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/17562848211005708

Source records